Search Results
Aug 05, 2026, 09:03 ET KeyBank Celebrates Third Anniversary of Key Select Checking® with Nearly $7 Million in Annual Bonuses Paid to Clients
eligibility. Eligibility is based on cumulative direct deposits in the preceding Evaluation Period. Your $100 bonus will be reported to the IRS on Form 1099-INT. Your $100 bonus will be deposited into your checking account within 30 calendar days after the Evaluation Period has expired. If your account is converted
More news about: KeyBank
Aug 04, 2026, 08:00 ET Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
https://event.choruscall.com/mediaframe/webcast.html?webcastid=bZ7JyAJEAbout INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Aug 03, 2026, 07:30 ET Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
PD diagnosis, PD-related symptoms, or a history of seeking treatment for the condition.ReferencesHellstrom WJ. Int J Impot Res. 2003;15(Suppl 5):S91–S92.Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.DiBenedetti
More news about: Keenova Therapeutics
Jul 30, 2026, 19:50 ET U.S. Renal Care Drives Innovation in Dialysis with Increased Availability of Medium Cut-Off Dialyzers to Support Expanded Hemodialysis
expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States. Hemodial Int. 2022;26(3):449-455. doi:10.1111/hdi.13015. PMID: 35441486; PMCID: PMC9544662. 12 Vantive. Vantive highlights late-breaking high
More news about: U.S. Renal Care
Jul 30, 2026, 08:30 ET CW Bancorp Reports Second Quarter 2026 Financial Results
Int Bearing Due from Banks & FFS$
More news about: CW Bancorp
Jul 30, 2026, 08:30 ET Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Illinois.9 Ghiani L, Chiocca S. High risk-human apillomavirus in HNSCC: Present and future challenges for pigenetic therapies. Int J Mol Sci. 2022;23(7):3483. doi.org/10.3390/ijms2307348310 Ferris RL, Blumenschein Jr G, Fayette J, et al. Nivolumab for recurrent
More news about: Johnson & Johnson
Jul 27, 2026, 10:31 ET Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
(Remibrutinib), Aravax (PVX108), ALK-Abelló (Sublingual Immunotherapy Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), Regeneron Pharmaceuticals (Linvoseltamab + Dupilumab), RAPT Therapeutics (RPT904), and several other innovators.LAS
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 08:00 ET Precision Diabetes and Nagase Diagnostics Announce Exclusive U.S. Commercialization Partnership for Lucica® Glycated Albumin-L, the Only FDA-Cleared Assay Specifically Measured Glycated Albumin in the United States
1;105(3):677–87.Peacock TP, etal., Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008 May;73(9):1062-8. Diabetes Care 2026;49(Supplement_1):S27–S49Zelnick LR, etal., Accuracy, Variability, and Bias of Glycemic Biomarkers
More news about: Precision Diabetes, Inc.
Jul 22, 2026, 09:00 ET First Community Corporation Announces Leadership Transition, Second Quarter Results and Increased Cash Dividend
3.47 % Int bearing deposits in other banks152,253
More news about: First Community Corporation
Jul 21, 2026, 09:00 ET RSM Survey: The Middle Market Has Embraced AI. Now Comes the Hard Part.
technical tax judgment and AI-enabled insight. Ultimately, the next phase of adoption of AI will be defined by how effectively organizations embed AI int the functions, workflows and decision that drive business performance."For more details on the survey's findings, the full report can be found
More news about: RSM US LLP
Jul 21, 2026, 07:00 ET Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
References[1] KDIGO 2017 Clinical Practice Guideline Update. Kidney Int Suppl. 2017;7(1):1–59.[2] Block GA, et al. J Am Soc Nephrol. 2004;15(8):2208–2218.[3] Tentori F, et al. Am J Kidney Dis.
More news about: Alebund Pharmaceuticals
Jul 15, 2026, 10:31 ET Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
and growing research activity supporting the development of novel therapeutic approaches, including TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6 (Intensity Therapeutics), ZEPZELCA (lurbinectedin) (PharmaMar/Jazz Pharmaceuticals), Pegargiminase (Polaris), and others.LAS
More news about: DelveInsight Business Research, LLP
Jul 15, 2026, 07:45 ET Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
achieve pCR, and ultimately an improved event-free survival." About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Jul 14, 2026, 11:15 ET LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jul 13, 2026, 17:36 ET FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jul 12, 2026, 11:15 ET LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jul 08, 2026, 09:04 ET Neuspera Integrated Sacral Neuromodulation System (iSNM) to Receive Same Medicare Payment as Legacy Implantable SNM Devices Under Proposed 2027 CMS Rule
M, Trump T, Zeinab MA, et al. Patients' Perspectives and Challenges with Implantable Pulse Generator in Patients Undergoing Sacral Neuromodulation. Int Urogynecol J. Published online June 9, 2026.Ball MAZ, Cheng MYZ, Mbassa R, Meeks W, Galen E, Van Kuiken ME. Trends in Utilization of Sacral
More news about: Neuspera Medical
Jul 07, 2026, 09:05 ET Merion Road Capital Management and Blue Hill Advisors urge United Bancorporation of Alabama to return excess capital, improve profitability, and strengthen corporate governance
Non-Int Bearing457
More news about: Merion Road Capital Management
Jul 01, 2026, 22:00 ET 越來越多年輕人受脫髮困擾：REGAINE®*培健引領毛髮科學研究發展
Liu JJ, Deng YY, Wu QF, Cao CY, Zhou LB, Lu Y, Fan WX. Early-onset androgenetic alopecia in China: a descriptive study of a large outpatient cohort. J Int Med Res. 2020 Mar;48(3):300060519897190. doi: 10.1177/0300060519897190. PMID: 32188323; PMCID: PMC7105740.
More news about: REGAINE®
Jul 01, 2026, 22:00 ET 越來越多年輕人受落髮困擾：REGAINE®*落建引領毛髮科學研究發展
Liu JJ, Deng YY, Wu QF, Cao CY, Zhou LB, Lu Y, Fan WX. Early-onset androgenetic alopecia in China: a descriptive study of a large outpatient cohort. J Int Med Res. 2020 Mar;48(3):300060519897190. doi: 10.1177/0300060519897190. PMID: 32188323; PMCID: PMC7105740.
More news about: REGAINE®
Jul 01, 2026, 08:00 ET Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
optionality and negotiating from a position of greater strength.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Jun 29, 2026, 09:00 ET NIH Awards Up to $4 Million to CraniUS Therapeutics to Advance Skull-Embedded Platform Designed to Bypass the Blood-Brain Barrier
www.craniusmed.com¹ Bernstock JD, et al. Recurrent Glioblastoma: Molecular Underpinnings and Evolving Treatment Paradigms. Int J Mol Sci. 2024;25(12):6733. PMID: 38928445. PMCID: PMC11203521.Investigational device. NeuroPASS is an investigational device and has
More news about: CraniUS Therapeutics
Jun 29, 2026, 07:30 ET Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference® 2026 (AAIC®)
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
doi:10.1016/S0140-6736(14)60763-7Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212. doi:10.1111/j.1365-4632.2011.05377.xMazzei Weiss ME. Vitiligo: to biopsy or not to biopsy?. Cutis.
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
doi:10.1016/S0140-6736(14)60763-7Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212. doi:10.1111/j.1365-4632.2011.05377.xMazzei Weiss ME. Vitiligo: to biopsy or not to biopsy?. Cutis.
More news about: AbbVie